Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 shall be determined as follows:
Appears in 2 contracts
Samples: Research Collaboration and License Agreement (Dynavax Technologies Corp), Research Collaboration and License Agreement (Dynavax Technologies Corp)
Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 7.2 shall be determined as follows:
Appears in 2 contracts
Samples: Licence Agreement (Flexion Therapeutics Inc), Licence Agreement (Flexion Therapeutics Inc)
Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 6.2 shall be determined as follows:
Appears in 2 contracts
Samples: Licence Agreement (Flexion Therapeutics Inc), Licence Agreement (Flexion Therapeutics Inc)
Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 8.2 shall be determined as follows:
Appears in 1 contract
Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 this Clause 15 shall be determined as follows:
Appears in 1 contract
Samples: Collaboration and Licence Agreement (Cambridge Antibody Technology Group PLC)
Combination Products. With respect to Combination Products, the Annual Net Sales used for the calculation of the royalties under Section 10.1 7.6 shall be determined as follows:
Appears in 1 contract
Samples: Collaboration and Licence Agreement (Virpax Pharmaceuticals, Inc.)